Biotech Drug Report Generated Sep 13, 2026

NMRA-511

NMRA·Neumora Therapeutics, Inc.

MIXED

Drug Impact Rating6/10

Trial Phase: Phase 1b/2a
Time to Market: At least 3-5 years away, assuming successful Phase 2 and Phase 3 trials. The drug is still in early clinical development (Phase 1b/2a).
Why 6/10: The next hard catalyst for NMRA-511 is the MAD expansion cohort data readout expected in Q4 2026 (within ~3 months). NMRA-511 is a significant pipeline asset but not the company's sole value driver (navacaprant for MDD is the lead program, and the company also has NMRA-898 and NMRA-215). A Phase 1b/2a readout is not a pivotal binary event, but positive data could meaningfully move the stock given the ~$1.04 share price and 380% implied analyst upside.

Actionable Insight ◆ MIXED

Watch for NMRA-511 MAD expansion cohort data in Q4 2026 — positive results could drive a significant rally given the stock's ~$1.04 price and 380% implied analyst upside, but negative data would pressure shares. The company has multiple shots on goal (navacaprant, NMRA-898, NMRA-215), so NMRA-511 is not a single-point-of-failure.

Price Chart

Loading chart...

Executive Summary

NMRA-511 is Neumora Therapeutics' Phase 1b/2a asset for Alzheimer's disease agitation, a vasopressin V1a receptor antagonist. Phase 1b data showed encouraging signals (Cohen's d 0.34 on CMAI total score, 0.51 on aggression sub-factor). The next catalyst is MAD expansion cohort data expected in Q4 2026, with a Phase 2 start planned by end of 2026. Neumora (NMRA) trades at ~$1.04 with $116.8M cash (runway into Q3 2027) and a market cap of ~$320M. While NMRA-511 is a promising pipeline asset, it is not the company's lead program (navacaprant for MDD is more advanced), and the stock faces headwinds from insider selling, cash burn, and the binary risk of early-stage clinical readouts.

How It Works

NMRA-511 is a vasopressin V1a receptor antagonist — it blocks a specific receptor in the brain involved in social and emotional behavior. By blocking this receptor, the drug aims to reduce agitation and aggression symptoms in Alzheimer's disease patients without the sedation side effects of current antipsychotic treatments.

Trial Status

Phase 1b single-ascending and multiple-ascending dose (SAD/MAD) study completed with data disclosed in Q1 2026. A MAD expansion cohort is ongoing with data expected in Q4 2026. Phase 2 start planned by end of 2026.

The Two-Sided Case

▲ Bull Case5

Phase 1b data showed encouraging efficacy signals: Cohen's d effect size of 0.34 on CMAI total score and 0.51 on aggression sub-factor in Alzheimer's agitation patients, suggesting meaningful clinical benefit.

Massive institutional accumulation in Q2 2026: BlackRock doubled its position (+279%), Geode doubled (+140%), Citadel doubled (+141%), and many other funds added or doubled positions, signaling institutional confidence.

Analyst consensus is strongly bullish: 12 Buy/Strong Buy ratings vs. 2 Hold and 1 Sell, with a mean price target of $6.14 implying ~380% upside from the current ~$1.04 price.

Alzheimer's agitation is a large unmet need with no FDA-approved treatments, representing a potentially multi-billion dollar market opportunity.

Cash runway into Q3 2027 ($116.8M) provides no near-term financing urgency, reducing dilution risk.

▼ Bear Case5

Phase 1b data is early and Cohen's d effect sizes from small studies often fail to replicate in larger, placebo-controlled Phase 2/3 trials — the 0.34-0.51 range may shrink or disappear.

Insider selling: COO Daljit Singh Aurora sold ~$500K+ worth of shares in mid-August 2026 at ~$1.50-1.65, well above the current ~$1.04 price, signaling insider caution.

The company is pre-revenue with a $43.1M quarterly net loss and $116.8M cash — at the current ~$33M quarterly burn rate, a capital raise may be needed by late 2027, causing dilution.

NMRA-511 is not the lead program; navacaprant (KOASTAL trials) is the primary value driver, and if navacaprant fails, NMRA-511 alone cannot support the valuation.

Competition from existing off-label antipsychotics and other developers targeting Alzheimer's agitation (e.g., AXS-05 from Axsome, pimavanserin from Acadia) creates a crowded landscape.

Upcoming Catalysts

NMRA-511 MAD expansion cohort data readout expected Q4 2026
NMRA-511 Phase 2 start expected by end of 2026
NMRA-898 Phase 1 schizophrenia data expected H2 2026
NMRA-215 IND submission expected Q4 2026

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Neumora Therapeutics, Inc. PRESS-RELEASE NMRA ·Originating report

Sources · 5

Hover a chip for the title

1 globenewswire.com2 globenewswire.com3 globenewswire.com4 sec.gov5 sec.gov